Bibliographic Details
| Title: |
FDA Approves Retifanlimab-dlwr for Merkel Cell Carcinoma |
| Authors: |
By:Hayley Virgil |
| Source: |
CancerNetwork (USA), March 22, 2023 News, 2pp |
| Abstract: |
The FDA has approved retifanlimab-dlwr (Zynyz) as a treatment for patients with metastatic or recurrent locally advanced Merkel cell carcinoma, according to a press release from Incyte. The biologic license application for the humanized monoclonal antibody received accelerated approval by the FDA based on data from the phase 2 POD1UM-201 trial (NCT03599713)... |
| Database: |
NewsBank |
